Antagonism of Adenosine A 1 or A 2A Receptors Amplifies the Effects of MDMA on Glial Activation in the Mouse Brain: Relevance to Caffeine–MDMA Interactions
Restricted accessResearch articleFirst published online June, 2014
Antagonism of Adenosine A 1 or A 2A Receptors Amplifies the Effects of MDMA on Glial Activation in the Mouse Brain: Relevance to Caffeine–MDMA Interactions
Previous studies by our group have demonstrated that caffeine, an antagonist of adenosine A1 and A2A receptors, amplifies the glial activation induced by 3,4-methylendioxymethamphetamine (MDMA, “ecstasy”) in mice. To elucidate the mechanisms underlying this effect, the present study evaluated whether selective antagonists for the A1 or the A2A adenosine receptor had any influence on MDMA-induced glial activation.
Methods:
MDMA (4×20 mg/kg) was administered to mice, alone or in combination with either the A1 antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.5 mg/kg) or the A2A antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c) pyrimidine (SCH 58261, 0.5 mg/kg). Immunoreactivity for complement type 3 receptor (CD11b) and glial fibrillary acidic protein (GFAP) was then studied in the striatum and substantia nigra pars compacta (SNc) to evaluate microglial and astroglial activation.
Results:
DPCPX amplified the elevation of both CD11b and GFAP immunoreactivity triggered by MDMA in the striatum, but did not affect MDMA-induced glial activation in the SNc. This effect was similar to that previously observed in mice treated with caffeine and MDMA in combination. Conversely, SCH 58261 potentiated MDMA-elicited elevation of CD11b immunoreactivity in both the striatum and SNc, but did not modify the effects of MDMA on GFAP in either region.
Conclusions:
These results demonstrate that both A1 and A2A receptors regulate MDMA-stimulated glial activation, and suggest that caffeine elicits the same effect chiefly by acting on A1 receptors.
Get full access to this article
View all access options for this article.
References
1.
ParrottAC. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology., 2004; 50:329–335.
2.
Tanner-SmithEE. Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. Drug Alcohol Depend., 2006; 83:247–254.
3.
ChengJY, ChanMF, ChanTW, HungMY. Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry. Forensic Sci Int., 2006; 162:87–94.
4.
GiraudonI, BelloPY. Monitoring ecstasy content in France: results from the National Surveillance System 1999–2004. Subst Use Misuse., 2007; 42:1567–1578.
5.
VogelsN, BruntTM, RigterS, van DijkP, VervaekeH, NiesinkRJ. Content of ecstasy in the Netherlands: 1993–2008. Addiction., 2009; 104:2057–2066.
6.
FredholmBB, BattigK, HolmenJ, NehligA, ZvartauEE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev., 1999; 51:83–133.
7.
McNamaraR, KeransA, O'NeillB, HarkinA. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (“Ecstasy”) and MDA (“Love”). Neuropharmacology., 2006; 50:69–80.
8.
McNamaraR, MaginnM, HarkinA. Caffeine induces a profound and persistent tachycardia in response to MDMA (“Ecstasy”) administration. Eur J Pharmacol., 2007; 555:194–198.
9.
Vanattou-SaifoudineN, McNamaraR, HarkinA. Mechanisms mediating the ability of caffeine to influence MDMA (‘Ecstasy’)-induced hyperthermia in rats. Br J Pharmacol., 2010; 160:860–877.
10.
BaumannMH, WangX, RothmanRB. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology., 2007; 189:407–424.
11.
CapelaJP, CarmoH, RemiaoF, BastosML, MeiselA, CarvalhoF. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol., 2009; 39:210–271.
12.
Gouzoulis-MayfrankE, DaumannJ. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction., 2006; 101:348–361.
13.
GranadoN, O'SheaE, BoveJ, VilaM, ColadoMI, MoratallaR. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem., 2008; 107:1102–1112.
14.
GreenAR, MechanAO, ElliottJM, O'SheaE, ColadoMI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev., 2003; 55:463–508.
15.
CostaG, FrauL, WardasJ, PinnaA, PlumitalloA, MorelliM. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord., 2013; 28:1957–1965.
16.
CostaG, SimolaN, MorelliM. MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology., 2014 [Epub ahead of print]; DOI: 10.1007/s00213-014-3536-z
17.
FrauL, SimolaN, PlumitalloA, MorelliM. Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem., 2013; 124; 69–78.
18.
OrioL, O'SheaE, SanchezV, et al. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem., 2004; 89:1445–1453.
19.
ThomasDM, DowgiertJ, GeddesTJ, Francescutti-VerbeemD, LiuX, KuhnDM. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett., 2004; 367:349–354.
20.
HallidayGM, StevensCH. Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord., 2011; 26:6–17.
21.
KhairnarA, PlumitalloA, FrauL, SchintuN, MorelliM. Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain. Neurotox Res., 2010; 17:435–439.
22.
GomesCV, KasterMP, TomeAR, AgostinhoPM, CunhaRA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta., 2011; 1808:1380–1399.
23.
HaskoG, PacherP, ViziES, IllesP. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci., 2005; 26:511–516.
24.
CartaAR, KachrooA, SchintuN, et al. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem., 2009; 111:1478–1489.
25.
HabergA, QuH, HaraldsethO, UnsgardG, SonnewaldU. In vivo effects of adenosine A1 receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with ex vivo 13C NMR spectroscopy. J Neurochem., 2000; 74:327–333.
26.
PinnaA, Di ChiaraG, WardasJ, MorelliM. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci., 1996; 8:1176–1181.
27.
PaxinosG, FranklinK. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press; 2001.
28.
GomesC, FerreiraR, GeorgeJ, et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation., 2013; 10:16.
29.
LuongoL, GuidaF, ImperatoreR, et al. The A1 adenosine receptor as a new player in microglia physiology. Glia., 2014; 62:122–132.
SebastiaoAM, RibeiroJA. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br J Pharmacol., 2009; 158:15–22.
32.
TsutsuiS, SchnermannJ, NoorbakhshF, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci., 2004; 24:1521–1529.
33.
CiccarelliR, BalleriniP, SabatinoG, et al. Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci., 2001; 19:395–414.
34.
HaselkornML, ShellingtonDK, JacksonEK, et al. Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma., 2010; 27:901–910.
35.
FredholmBB, IreniusE, KullB, SchulteG. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol., 2001; 61:443–448.
36.
BovéJ, SerratsJ, MengodG, CortésR, TolosaE, MarinC. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res., 2005; 165:362–374.
37.
FrauL, BorsiniF, WardasJ, KhairnarAS, SchintuN, MorelliM. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse., 2011; 65:181–188.
38.
SchwarzschildMA, XuK, OztasE, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology., 2003; 61:S55–S61.
39.
SimoesAP, DuarteJA, AgasseF, et al. Blockade of adenosine A2A receptors prevents interleukin-1beta-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway. J Neuroinflammation., 2012; 9:204.
40.
Ruiz-MedinaJ, LedentC, CarretonO, ValverdeO. The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA. J Psychopharmacol., 2011; 25:550–564.
41.
BlumD, GalasMC, PintorA, et al. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci., 2003; 23:5361–5369.
42.
DaiSS, ZhouYG, LiW, et al. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci., 2010; 30:5802–5810.
43.
AnnekenJH, CunninghamJI, CollinsSA, YamamotoBK, GudelskyGA. MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. J Neuroimmune Pharmacol., 2013; 8:58–65.
44.
AnnekenJH, GudelskyGA. MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology., 2012; 63:1022–1027.
